세계의 원내감염 대책 시장 : 인사이트, 경쟁 구도 및 시장 예측(2030년)

Hospital Acquired Infection Control Market By Product Type (Disinfectants, Sterilant [Heat Sterilization Equipment, Low Temperature Sterilization Equipment, Radiation Sterilization Equipment, Steam Sterilization, And Others], And Others), By Application Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections, And Others), By End User (Hospitals And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to increased incidence of hospital-acquired infections and increase in number of surgical procedures

Global hospital acquired infection control market was valued at USD 28.76 billion in 2023, growing at a CAGR of 3.18% during the forecast period from 2024 to 2030 to reach USD 35.42 billion by 2030. The increase in demand for hospital acquired infection control products is primarily attributed to the high rate of inpatient stay among patients due to high prevalence of chronic disorders globally and the increase in number of surgical procedures across the world. Moreover, the increase in incidence of hospital-acquired infections and the growing number of geriatric population prone to chronic disorders are anticipated to bolster the market, thereby contributing to the growth of the hospital acquired infection control market during the forecast period from 2024-2030.

Hospital Acquired Infection Control Market Dynamics:

The hospital acquired infection control market is witnessing a growth in product demand owing to various reasons.

The increasing prevalence of hospital acquired infection globally is anticipated to bolster the market for hospital acquired infection control during the forecasted period. For instance, according to World Health Organization (WHO) 2022, it was estimated that globally hundreds of millions of people every year are affected by health care-associated infections (HAIs), many of which are completely avoidable. As per the same source, it was reported that out of every 100 patients, 7 patients are in high- and 15 patients in low-/middle-income countries. WHO also concluded that globally, 1 in every 10 affected patients dies of the hospital acquired infection.

Moreover, according to Centers for Disease Control and Prevention (CDC), 2020 Annual National and State Healthcare-Associated Infections (HAI) Progress Report, it was estimated that between 2019 and 2020 in the United States, about 24% increase is seen in central line-associated bloodstream infections (CLABSI) with largest increase in infections transmitted from ICU. From the above stats it can be concluded that, the prevalence of hospital acquired infection is increasing globally. The increasing prevalence and mortality from the infection can be controlled by following proper measures such as maintaining proper hand hygiene, wearing mask, gloves, and other protective gears, disinfecting the area subjected to contamination, and following proper sterilization of all the equipment used in the hospitals, owing to increase the demand of hospital acquired infection control products. Thus, propelling the overall market growth of hospital acquired infection control products in the year 2023 - 2028.

Additionally, the rise in prevalence of chronic diseases like IBD, gastroesophageal reflux disease (GERD), peptic ulcer disease, crohn's disease, diabetes, hypertension, cardiovascular disorders, cancer, and others due to environmental pollution, smoking, unhealthy lifestyles, poor nutrition and diet, and high intake of carcinogenic substances will drive the market of hospital acquired infection control devices. For instance, according to International Diabetes Federation, Diabetes Atlas 10th edition report 2022, globally 537 million adults (20-79 years) are living with diabetes. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. The rising prevalence of chronic disease will also increase the number of surgical procedures. The increasing number of surgeries will increase the risk of hospital acquired infections. The transition of infections can be ceased by following proper sterilization and disinfectant techniques. Therefore, the rising number of surgical procedures owing to the rising prevalence of chronic disorders may increase the prevalence of hospital acquired infections ultimately increasing the demand of hospital acquired infection control product. Thus the above factor is anticipated to increase the overall market growth of the hospital acquired infection control products in the year 2023 - 2028.

Another factor which will affect the market in the year 2023 - 2028 is the increasing number of geriatric population. According to WHO 2019, in the year 2019, the number of people aged 60 years and older were 1 billion. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. This increase is occurring at an unprecedented pace and is expected to accelerate in coming decades, particularly in developing countries. The possibility of having a chronic disorder or cancer is higher in the older age, so as the number of geriatric population is increasing, this will increase the probability of increasing prevalence of a chronic ailment in geriatric population. This will lead to an increase in the number of in-patient hospital stay, further leading to increased risk of hospital acquired infection. This will ultimately increase the demand of hospital acquired infection control products, thereby bolstering the overall market growth.

However, the adverse effects of chemical disinfectants and higher cost of advanced sterilization instruments may act as a limiting factors of the hospital acquired infection control products market growth.

The ongoing COVID-19 pandemic has positively impacted the market for hospital acquired infection control. At the onset of the disease, there was a significant shortage in the devices, attributed to the imposition of stringent lockdowns to curb the spread of the virus so the production of some medical devices was shut down. However, the infection control devices were used in pandemic to avoid the transmission of the infection. Admission of patients suffering from coronavirus was higher in the hospitals so the demand of infection control devices increased during the pandemic. Moreover, the hospital acquired infection was one of the major risk factor for patients suffering from coronavirus. Therefore, the increasing number of hospital acquired infection during the pandemic increased the demand of the infection control products globally, thereby impacting the overall market positively.

Hospital Acquired Infection Control Market Segment Analysis:

Hospital Acquired Infection Control by Product Type (Disinfectants, Sterilant [Heat Sterilization Equipment, Low Temperature Sterilization Equipment, Radiation Sterilization Equipment, Steam Sterilization, and Others], and Others), by Application Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections, and Others), by End-User (Hospitals And Clinics, Ambulatory Surgical Centers, and Others) and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the hospital acquired infection control market, the disinfectant segment is estimated to hold a significant share in the hospital acquired infection control market in the year 2023. This can be ascribed to the various advantages associated with the category.

The demand for disinfectant is expected to increase during the forecast period. The COVID-19 pandemic has significantly impacted the growth of the disinfectant market. The usage of disinfectant was higher in hospitals during the pandemic as the number of hospitalization increased during this time. The prime aim of disinfectants is that it provides protection in healthcare facilities and safeguard personnel performing medical procedures that expose them to the virus. Disinfectants kills viruses and bacteria on surfaces using chemicals. Therefore, the transmission of viral infection can be ceased by using disinfectants on the hospital equipment, thereby leading to increased demand of disinfectants in the market.

Further, the disinfectants take very small time to kill the bacteria or virus present on any surface. Additionally, the disinfectants are generally nontoxic, non-irritating, inexpensive, and non-allergenic.

Moreover, the product launches in local market, in turn, drive the product demand in the market. For instance, in March 2022, PDI, is an infection prevention company announced the dual launch of novel, innovative disinfectants to help infection prevention professionals in the fight against rising healthcare-associated infections (HAIs) as well as the ongoing battle against Covid-19. The new products were Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe and Sani-HyPerCide Germicidal Spray.

Thus, owing to the advantages and increased demand after pandemic as well as product launch, there will be an increase in the demand for disinfectants, which in turn will drive the hospital acquired infection control products market growth.

North America is expected to dominate the overall Hospital Acquired Infection Control Market:

Among all the regions, North America is expected to account for the largest share in the global hospital acquired infection control market. The growing incidence of chronic diseases such as cancer, kidney disease, crohn's disease, growing incidence of hospital acquired infections and the high geriatric population will increase the demand for hospital acquired infection control in North America, leading to a rise in the overall hospital acquired infection control market growth. Further, the increasing demand and awareness of infection control protocols and, improved healthcare expenditure among the region will bolster the overall market of hospital acquired infection control devices in the forecast period of 2022 - 2028.

For instance, according to Government of Canada 2022, by the year 2030 seniors are expected to over 9.5 million and make up 23% of Canadians. Moreover, as per the same source, by 2036, the average life expectancy at birth for women will rise to 86.2 years from the current 84.2 and to 82.9 years from the current 80 for men. The geriatric patients are more susceptible to cancer and chronic ailments owing to the increased hospital admissions. The increasing hospital admissions of the geriatric patients may surge the risk of hospital acquired infections. The infection can be controlled by using sterilized and disinfectant hospital equipment's and by using various consumables like gloves, mask, hand sanitizers, and others. Thus, the rising number of geriatric patients will increase the number of hospitalization ultimately increasing prevalence of hospital acquired infection will increase the demand of hospital acquired infection control devices. Henceforth, increasing the overall market growth of the hospital acquired infection control in the forecast period in the region.

Moreover, the innovative technologies implemented in products that control infection, awareness regarding the use of personalized medicines, and cost-effective techniques to treat hospital-acquired infections are some of the factors that have been driving the growth of the hospital acquired infection control devices market.

Thus, all the above-mentioned factors are anticipated to propel the market for Hospital Acquired Infection Control in the North America.

Hospital Acquired Infection Control Market Key Players:

Some of the key market players operating in the hospital acquired infection control market include 3M Company, BD, Getinge AB, STERIS PLC, Sotera Health, Fortive Corporation, Tuttnauer, Xenex Disinfection Services Inc., ASP, Ecolab, bombayengg, BIONICS SCIENTIFIC TECHNOLOGIES (P) LTD., Systec GmbH, Thermo Fisher Scientific, Spectrum Chemical, among others.

Recent Developmental Activities in the Hospital Acquired Infection Control Market:

In September 2022, Sodexo, a global leader in services that improve Quality of Life announced that the company has expanded its partnership with Ecolab in the United States for the control of hospital-acquired infections through the Protecta Plus programme. This programme was created to reduce infection risk in hospitals and healthcare facilities by utilizing Ecolab's Bioquell hydrogen peroxide vapour technology.

In June 2022, STERIS plc, provider of innovative healthcare and life science products and services around the globe announced that it has completed the acquisition of Cantel Medical, a global provider of infection prevention products and services to endoscopy, dental, dialysis and life sciences Customers.

In December 2020, Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, announced the acquisition of vanBaerle Hygiene AG, a privately held hygiene provider in Switzerland. VanBaerle offers a full range of cleaning, disinfectant and hygiene solutions.

In October 2020, Getinge, provide hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows announced the launch of the Getinge Solsus 66 steam sterilizer for hospitals and surgical instruments with increased capacity and operational reliability compared to other sterilizers

Key Takeaways from the Hospital Acquired Infection Control Market Report Study

• Market size analysis for current hospital acquired infection control market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hospital acquired infection control market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global hospital acquired infection control market.
• Various opportunities available for the other competitor in the hospital acquired infection control market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current hospital acquired infection control market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for hospital acquired infection control market growth in the coming future?

Target Audience who can be benefited from this Hospital Acquired Infection Control Market Report Study

• Hospital acquired infection control products providers
• Research organizations and consulting companies
• Hospital acquired infection control-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in hospital acquired infection control
• Various End-users who want to know more about the hospital acquired infection control market and latest technological developments in the hospital acquired infection control market.

Frequently Asked Questions for Hospital Acquired Infection Control Market:

1. What are Hospital Acquired Infection Control?

Healthcare-Acquired Infections (HAIs) also called as Healthcare-Associated Infections, are infections that a patient gets while receiving treatment at a healthcare facility, like a hospital, or from a healthcare professional, like a doctor or nurse. The measures taken to control the transmission of hospital acquired infection is known as hospital acquired infection control.

2. What is the market for Global Hospital Acquired Infection Control?

Global Hospital Acquired Infection Control market was valued at USD 28.76 billion in 2023, growing at a CAGR of 3.18% during the forecast period from 2024 to 2030 to reach USD 35.42 billion by 2030.

3. What are the drivers for the Global Hospital Acquired Infection Control Market?

The hospital acquired infection control market is witnessing a positive market growth owing to the high rate of inpatient stay among patients due to increase in number of chronic disorders. Moreover, increase in number of surgical procedures will drive the market of hospital acquired infection control devices as during the surgical procedures certain hospital acquired infections are observed in the patients. Additionally, the growing number of geriatric population prone to chronic disorder across the world are anticipated to bolster the market.

4. Who are the key players operating in the global hospital acquired infection control market?

Some of the key market players operating in the hospital acquired infection control market include 3M Company, BD, Getinge AB, STERIS PLC, Sotera Health, Fortive Corporation, Tuttnauer, Xenex Disinfection Services Inc., ASP, Ecolab, bombayengg, BIONICS SCIENTIFIC TECHNOLOGIES (P) LTD., Systec GmbH, Thermo Fisher Scientific, Spectrum Chemical, and others.

5. Which region has the highest share in hospital acquired infection control market?

North America is expected to hold the highest share in the revenue in the hospital acquired infection control market during the forecast period. Increase in number of surgical procedures and increase in incidence of hospital-acquired infections will increase the demand for hospital acquired infection control devices in North America, leading to a rise in the overall hospital acquired infection control market growth in this region.

Table of Contents

1.Hospital Acquired Infection Control Market Report Introduction

2.Hospital Acquired Infection Control Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Hospital Acquired Infection Control Market Key Factors Analysis

• 4.1. Hospital Acquired Infection Control Market Drivers
  • 4.1.1. High rate of inpatient stay among patients due to chronic disorders
  • 4.1.2. Increase in number of surgical procedures
  • 4.1.3. Increase in incidence of hospital-acquired infections
  • 4.1.4. Growing number of geriatric population prone to chronic disorder
• 4.2. Hospital Acquired Infection Control Market Restraints and Challenges
  • 4.2.1. Adverse effects of chemical disinfectants
  • 4.2.2. Higher cost of advanced instruments
• 4.3. Hospital Acquired Infection Control Market Opportunities
  • 4.3.1. Increasing adoption of disinfectant robots

5. Hospital Acquired Infection Control Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Hospital Acquired Infection Control Market

7. Hospital Acquired Infection Control Market Layout

• 7.1. By Product Type
  • 7.1.1. Disinfectants
  • 7.1.2. Sterilant
    • 7.1.2.1. Heat Sterilization Equipment
    • 7.1.2.2. Low Temperature Sterilization Equipment
    • 7.1.2.3. Radiation Sterilization Equipment
    • 7.1.2.4. Steam Sterilization
    • 7.1.2.5. Others
  • 7.1.3. Others
• 7.2. By Application Type
  • 7.2.1. Hospital Acquired Pneumonia
  • 7.2.2. Bloodstream Infections
  • 7.2.3. Surgical Site Infections
  • 7.2.4. Gastrointestinal Infections
  • 7.2.5. Urinary Tract Infections
  • 7.2.6. Others
• 7.3. By End User
  • 7.3.1. Hospitals and Clinics
  • 7.3.2. Ambulatory Surgical Centers
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. North America Hospital Acquired Infection Control Market, by Country
    • 7.4.1.1.1. United States
    • 7.4.1.1.2. Canada
    • 7.4.1.1.3. Mexico
  • 7.4.2. Europe
    • 7.4.2.1. Europe Hospital Acquired Infection Control Market, by Country
    • 7.4.2.1.1. France
    • 7.4.2.1.2. Germany
    • 7.4.2.1.3. United Kingdom
    • 7.4.2.1.4. Italy
    • 7.4.2.1.5. Spain
    • 7.4.2.1.6. Russia
    • 7.4.2.1.7. Rest of Europe
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. Asia-Pacific Hospital Acquired Infection Control Market, by Country
    • 7.4.3.1.1. China
    • 7.4.3.1.2. Japan
    • 7.4.3.1.3. India
    • 7.4.3.1.4. Australia
    • 7.4.3.1.5. South Korea
    • 7.4.3.1.6. Rest of Asia Pacific
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. RoW Hospital Acquired Infection Control Market, by Region
    • 7.4.4.1.1. Middle East
    • 7.4.4.1.2. Africa
    • 7.4.4.1.3. South America

8. Hospital Acquired Infection Control Market Global Company Share Analysis - Key 3-5 Companies

9. Hospital Acquired Infection Control Market Company and Product Profiles

• 9.1. 3M Company
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. BD
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Getinge AB
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. STERIS PLC
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Sotera Health
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Fortive Corporation
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Tuttnauer
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Xenex Disinfection Services Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. ASP
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Ecolab
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. bombayengg
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. BIONICS SCIENTIFIC TECHNOLOGIES (P) LTD.
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Systec GmbH
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Thermo Fisher Scientific
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Spectrum Chemical
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us